Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Chicago Atlantic Group, LP and its affiliates have made substantial acquisitions of Vireo Growth Inc. (NASDAQ:VREO) stock, according to recent filings. Over a series of transactions in March 2025, Chicago Atlantic acquired a total of 190,500 subordinate voting shares. These purchases were made at prices ranging from $0.3239 to $0.3673 per share, with the stock showing significant volatility according to InvestingPro data. The company, currently valued at $134.8 million by market capitalization, has seen an 8.2% return over the past week despite challenging market conditions. Additionally, a significant transaction at the end of 2024 involved the acquisition of 32,032,000 shares at $0.625 each, contributing to a total acquisition value of approximately $20.1 million. These transactions reflect a notable increase in Chicago Atlantic’s holdings in Vireo Growth, a company engaged in pharmaceutical preparations. InvestingPro analysis reveals the company operates with a moderate debt level and maintains a current ratio of 1.7, though it’s currently burning through cash rapidly. Discover more insights about VREO and access comprehensive Pro Research Reports covering 1,400+ US equities on InvestingPro.
In other recent news, Vireo Growth Inc. reported a 15.4% increase in full-year revenue, reaching $99.4 million, with fourth-quarter revenue up 3.5% to $25 million. Despite these gains, the company posted a net loss of $15.7 million for the fourth quarter, attributed to one-time transaction expenses. Vireo Growth plans to transform its operations with a new cultivation facility in Minnesota and the expansion into adult-use sales. The company ended the year with a strong cash position of $91.6 million. Analysts noted the company’s strategic focus on capital deployment to drive high returns for shareholders, particularly in New York and Minnesota. Vireo Growth’s upcoming merger transactions, expected to close in 2025, are also part of its growth strategy. The company anticipates significant contributions from its New York facility starting in the second quarter of 2025. The firm’s focus on building a portfolio of cannabis brands remains central to its future plans.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.